CAMP4 Therapeutics Receives CTA Approval From Regulatory Authorities And Ethics Committees Of Multiple EU Countries To Initiate Global Phase 1/2 ASCEND Clinical Trial Of CMP-002 At Trial Sites In European Union
Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002Company on track to
Share
Why It Matters
CAMP4 got permission to test a new medicine in Europe. This is a step forward in trying out the drug on people.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.